Here we investigated the effect of the rivastigmine patch alone on depression in 50 mild Alzheimer's Disease (AD) patients with comorbid major depressive episode (MDE). First diagnosis acetyl-cholinesterase inhibitor and psychoactive drug-free outpatients (n=50) were recruited in memory clinics and reassessed after 3 and 6 months. Global cognitive functioning, depressive symptoms and MDE frequency were evaluated with the Mini Mental State Examination, the CERAD Dysphoria scale and the modified DSM-IV criteria for MDE in AD. MDE frequency reduced significantly from the first diagnostic visit (100%) to the 6-month follow-up (62%). We also found a significant reduction in CERAD Dysphoria scores that decreased from 6.2 +/- 3.9 mean +/- standard deviation to 4.9 +/- 4.5 at the 6-month follow-up. In AD patients with MDE rivastigmine alone can have a positive impact on depressive phenomena. Thus, future controlled study are justified to definitively verify if rivastigmine alone may improve depression in AD.
Rivastigmine Patch Ameliorates Depression in Mild AD: Preliminary Evidence From a 6-Month Open-label Observational Study / Gianfranco, Spalletta; Walter, Gianni; Giubilei, Franco; Anna R., Casini; Giuseppe, Sancesario; Carlo, Caltagirone; Luca, Cravello. - In: ALZHEIMER DISEASE & ASSOCIATED DISORDERS. - ISSN 0893-0341. - STAMPA. - 27:3(2013), pp. 289-291. [10.1097/wad.0b013e318260ab0a]
Rivastigmine Patch Ameliorates Depression in Mild AD: Preliminary Evidence From a 6-Month Open-label Observational Study
GIUBILEI, Franco;
2013
Abstract
Here we investigated the effect of the rivastigmine patch alone on depression in 50 mild Alzheimer's Disease (AD) patients with comorbid major depressive episode (MDE). First diagnosis acetyl-cholinesterase inhibitor and psychoactive drug-free outpatients (n=50) were recruited in memory clinics and reassessed after 3 and 6 months. Global cognitive functioning, depressive symptoms and MDE frequency were evaluated with the Mini Mental State Examination, the CERAD Dysphoria scale and the modified DSM-IV criteria for MDE in AD. MDE frequency reduced significantly from the first diagnostic visit (100%) to the 6-month follow-up (62%). We also found a significant reduction in CERAD Dysphoria scores that decreased from 6.2 +/- 3.9 mean +/- standard deviation to 4.9 +/- 4.5 at the 6-month follow-up. In AD patients with MDE rivastigmine alone can have a positive impact on depressive phenomena. Thus, future controlled study are justified to definitively verify if rivastigmine alone may improve depression in AD.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
